Skip to main content

Thank you for visiting nature.com. You are using a browser version with limited support for CSS. To obtain the best experience, we recommend you use a more up to date browser (or turn off compatibility mode in Internet Explorer). In the meantime, to ensure continued support, we are displaying the site without styles and JavaScript.

  • From the Analyst's Couch
  • Published:

Antibody–drug conjugates

Nature Reviews Drug Discovery volume 12, pages 259–260 (2013)Cite this article

Subjects

Second-generation ADCs

At the forefront of this new wave of ADC development is brentuximab vedotin, a CD30-specific ADC that was approved by the US Food and Drug Administration (FDA) in August 2011 to treat Hodgkin's lymphoma and systemic anaplastic large cell lymphoma. It was developed through a partnership between Millennium (The Takeda Oncology Group) and Seattle Genetics, using the proprietary linker and cytotoxic platform technology of Seattle Genetics. Sales of brentuximab vedotin in the United States were US$136 million (October 2011 to September 2012) in a relatively small patient population.

This is a preview of subscription content, access via your institution

Access options

Buy this article

  • Purchase on Springer Link
  • Instant access to full article PDF
Buy now

Prices may be subject to local taxes which are calculated during checkout

Figure 1: Antibody–drug conjugate structure and desired characteristics.

References

  1. Hughes, B. Antibody–drug conjugates for cancer: poised to deliver? Nature Rev. Drug Discov. 9, 665–667 (2010).

    Article  CAS  Google Scholar 

  2. Lash, A. Antibody–drug conjugates: the next generation of moving parts. START-UP 27 Dec 2011 (Article #2011900259).

  3. Seattle Genetics. 2012 press releases. Seattle Genetics website [online], (2012).

Download references

Author information

Authors and Affiliations

  1. Rachel S. Zolot, Satarupa Basu and Ryan P. Million are at Trinity Partners, 675 Third Avenue, 20th Floor, New York, New York 10017, USA.,

    Rachel S. Zolot, Satarupa Basu & Ryan P. Million

Authors
  1. Rachel S. Zolot
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Satarupa Basu
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Ryan P. Million
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding authors

Correspondence to Rachel S. Zolot or Ryan P. Million.

Rights and permissions

Reprints and permissions

About this article

Cite this article

Zolot, R., Basu, S. & Million, R. Antibody–drug conjugates. Nat Rev Drug Discov 12, 259–260 (2013). https://doi.org/10.1038/nrd3980

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1038/nrd3980

This article is cited by

Search

Advanced search

Quick links

Nature Briefing: Translational Research

Sign up for the Nature Briefing: Translational Research newsletter — top stories in biotechnology, drug discovery and pharma.

Get what matters in translational research, free to your inbox weekly. Sign up for Nature Briefing: Translational Research